Company profile
Lipocine Inc.
NASDAQ:LPCNBiotechnology: Pharmaceutical Preparations
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04685993 | phase2 | completed | 2020-11-11 | 2022-03-01 | Lipocine Inc. | A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial |
| NCT04874350 | phase2 | completed | 2021-11-30 | 2023-12-18 | Lipocine Inc. | A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia |
| NCT06979544 | phase3 | completed | 2025-06-16 | 2026-01-16 | Lipocine Inc. | A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD |
| NCT03868059 | phase3 | completed | 2018-04-30 | 2019-02-19 | Lipocine Inc. | Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men |
| NCT03242408 | phase3 | completed | 2017-01-01 | 2017-05-01 | Lipocine Inc. | Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) |
FDA applications (0)
No records yet.